Teva’s $40.5 billion acquisition of Allergan’s generics business, formerly known as Actavis, has gone ahead as planned – and the generics mega-merger is set to impact the UK. In order to ...

India’s Intas has signed a deal to buy a UK generics business from Teva for £600 million, a sell-off required because of EU competition rules. Teva earlier this year bought the Actavis generics ...

Teva Pharmaceutical (NYSE ... company's decision to rely heavily on U.S. generics via its $41B buyout of Actavis Generics in 2016. "Upon further reflection and dialogue with management, we believe ...

Now, the Florida-based drugmaker has parried another Firdapse challenger in Teva Pharmaceuticals, which had hoped to market a generic version of the Lambert-Eaton myasthenic syndrome (LEMS ...

We view Teva's investments as fair. The purchase of Actavis, Allergan's generics business, for $40.5 billion in 2016 destroyed an enormous amount of value, racking up a large amount of debt and ...

Saddled with nearly $35 billion in debt since acquiring Allergan's Actavis generic drug business for $40.5 billion, Teva made a series of changes after Kare Schultz joined as its new chief ...

CMS's redefinition pulls drugs into price control sooner, reducing market opportunities for generics and biosimilars. CMS replaces Congress's clear eligibility test with subjective criteria ...

With more than five dozen generics already tentatively approved for 10 of the drugs selected for the next round of the Medicare Price Negotiation Program, the impact of the negotiations won’t be ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...